| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $22.3M | -11.5% |
| R&D Expense | $50.0M | +37.1% |
| SG&A Expense | $14.9M | +16.1% |
| Operating Income | -$42.6M | -76.8% |
| Net Income | -$40.5M | -81.6% |
| EPS (Basic) | -$1.15 | -38.6% |
| EPS (Diluted) | -$1.15 | -38.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $11.3M | -23.2% |
| Short-term Investments | $140.2M | +465.6% |
| Current Assets | $163.4M | +221.3% |
| Total Assets | $170.5M | +190.3% |
| Current Liabilities | $21.0M | -32.8% |
| Total Liabilities | $25.0M | -30.8% |
| Stockholders' Equity | $145.5M | +543.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$40.0M | -56.3% |
| Capital Expenditures | $1.2M | -11.0% |
| Investing Cash Flow | -$116.2M | -2374.5% |
| Financing Cash Flow | $152.8M | +497.2% |
| Free Cash Flow | -$41.2M | -53.0% |